Sigmanomics
Back to all insights

Regeneron Pharmaceuticals Inc. (REGN) Investors Alert: Don’t Lose Hope, Contact Levi & Korsinsky for Ongoing Investigation!

Regeneron Pharmaceuticals Inc. (REGN) Investors Alert: Don’t Lose Hope, Contact Levi & Korsinsky for Ongoing Investigation!

Investigating Regeneron Pharmaceuticals Inc.

Introduction

Levi & Korsinsky, a renowned law firm, has recently announced that they are investigating Regeneron Pharmaceuticals Inc. for possible violations of federal securities laws. This investigation has been initiated following the release of Regeneron’s third-quarter financial results for 2024.

Financial Results

On October 31, 2024, Regeneron reported that their U.S. net sales for EYLEA HD® and EYLEA® had increased by 3% compared to the third quarter of 2023, reaching a total of $1.54 billion. This amount includes $392 million from EYLEA HD.

Investors Alert

Levi & Korsinsky is urging investors who may have suffered losses due to their investment in Regeneron Pharmaceuticals Inc. to contact them for more information about the ongoing investigation. It is important for investors to be aware of their rights and options in such situations.

What to Do Next?

If you are an investor in Regeneron Pharmaceuticals Inc. and have concerns about your investment, don’t lose hope. Contact Levi & Korsinsky to stay informed about the ongoing investigation and learn about your legal options moving forward.

How This Will Affect You

Personal Impact

As an investor in Regeneron Pharmaceuticals Inc., this ongoing investigation could potentially have a direct impact on your investments. It is important to stay informed about the situation and consider reaching out to Levi & Korsinsky for guidance on how to proceed.

How This Will Affect the World

Global Impact

The investigation of Regeneron Pharmaceuticals Inc. could have wider implications for the pharmaceutical industry as a whole. Any findings of violations of federal securities laws could lead to increased scrutiny and regulations within the industry, ultimately impacting how pharmaceutical companies operate and interact with investors.

Conclusion

Stay Informed

Investors in Regeneron Pharmaceuticals Inc. are advised to stay informed about the ongoing investigation initiated by Levi & Korsinsky. By understanding their rights and options, investors can make informed decisions about their investments and protect their interests.

more insights

“Breaking News: President Trump Opens Doors for Banks to Safely Store Bitcoin and Other Crypto Assets with the Elimination of SAB 121”

January 24, 2025

President Trump has officially eliminated a controversial guideline from the U.S. Securities and Exchange Commission that effectively prevented US banks from holding crypto assets. The new administration just rescinded Staff Accounting Bulletin 121, which forced banks to identify crypto assets held on behalf of their customers as liabilities on their

Read more >
Sigmanomics

Menu

About

News

Signals

Risk Disclaimer: Sigmanomics is a financial portal that provides news and analysis about the different financial markets. The articles that we serve on the portal depend solely on the opinion and analysis of our economists which in no way are intended to incite a visitor of the website or an investor to trade or sell/buy a certain instrument. It is the responsibility of the visitor / trader only to evaluate his trading strategies and whether he is capable of trading with taking into consideration that losing all the capital invested is a possibility. The visitor should seek an independent professional financial advisor to discuss his or her trading strategies. Moreover, the provided rates for the different instruments are indicative only and cannot be used for trading purposes. Therefore, no responsibility can be imposed on sigmanomics.com.com and the company operating the portal for any loss of money that may occur to the visitor by using the website.